These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 15768338)

  • 1. Medical examinations at entry to treatment for drug abuse as an opportunity to initiate care for hepatitis C virus infection.
    Hagan H; Strauss SM; Astone JM; Des Jarlais DC
    Clin Infect Dis; 2005 Apr; 40 Suppl 5():S297-303. PubMed ID: 15768338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of HCV antibody testing in drug-free and methadone maintenance treatment programs in the United States.
    Strauss SM; Astone JM; Jarlais DD; Hagan H
    Drug Alcohol Depend; 2004 Mar; 73(3):227-36. PubMed ID: 15036545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using latent class analysis to identify patterns of hepatitis C service provision in drug-free treatment programs in the U.S.
    Strauss SM; Rindskopf DM; Astone-Twerell JM; Des Jarlais DC; Hagan H
    Drug Alcohol Depend; 2006 Jun; 83(1):15-24. PubMed ID: 16289523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities.
    Litwin AH; Soloway I; Gourevitch MN
    Clin Infect Dis; 2005 Apr; 40 Suppl 5():S339-45. PubMed ID: 15768345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrating care for hepatitis C virus (HCV) and primary care for HIV for injection drug users coinfected with HIV and HCV.
    Kresina TF; Bruce RD; Cargill VA; Cheever LW
    Clin Infect Dis; 2005 Jul; 41 Suppl 1():S83-8. PubMed ID: 16265621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence rates and risk factors for hepatitis C among drug users not in treatment in Malaysia.
    Vicknasingam B; Narayanan S; Navaratnam V
    Drug Alcohol Rev; 2009 Jul; 28(4):447-54. PubMed ID: 19594801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of hepatitis C among drug users attending general practice in Ireland: baseline data from the Dublin area hepatitis C in general practice initiative.
    Cullen W; Stanley J; Langton D; Kelly Y; Bury G
    Eur J Gen Pract; 2007; 13(1):5-12. PubMed ID: 17366287
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nutrition education is positively associated with substance abuse treatment program outcomes.
    Grant LP; Haughton B; Sachan DS
    J Am Diet Assoc; 2004 Apr; 104(4):604-10. PubMed ID: 15054346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Integrating hepatitis, STD, and HIV services into a drug rehabilitation program.
    Gunn RA; Lee MA; Callahan DB; Gonzales P; Murray PJ; Margolis HS
    Am J Prev Med; 2005 Jul; 29(1):27-33. PubMed ID: 15958248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Knowledge of and interest in hepatitis C treatment at a methadone clinic.
    Walley AY; White MC; Kushel MB; Song YS; Tulsky JP
    J Subst Abuse Treat; 2005 Mar; 28(2):181-7. PubMed ID: 15780548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy.
    Hallinan R; Byrne A; Amin J; Dore GJ
    J Gastroenterol Hepatol; 2005 Jul; 20(7):1082-6. PubMed ID: 15955218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcome of screening for hepatitis C virus infection based on risk factors.
    Mallette C; Flynn MA; Promrat K
    Am J Gastroenterol; 2008 Jan; 103(1):131-7. PubMed ID: 17894850
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-related quality of life in methadone maintenance patients with untreated hepatitis C virus infection.
    Batki SL; Canfield KM; Smyth E; Ploutz-Snyder R
    Drug Alcohol Depend; 2009 May; 101(3):176-82. PubMed ID: 19233573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the French national plan to promote screening and early management of viral hepatitis C, between 1997 and 2003: a comparative cross-sectional study in Poitou-Charentes region.
    Defossez G; Verneau A; Ingrand I; Silvain C; Ingrand P; Beauchant M;
    Eur J Gastroenterol Hepatol; 2008 May; 20(5):367-72. PubMed ID: 18403936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opportunities to address the hepatitis C epidemic in the correctional setting.
    Boutwell AE; Allen SA; Rich JD
    Clin Infect Dis; 2005 Apr; 40 Suppl 5():S367-72. PubMed ID: 15768350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does psychiatric comorbidity affect drug abuse treatment outcome? A prospective assessment of drug abuse, treatment tenure and infectious diseases in an Israeli methadone maintenance clinic.
    Gelkopf M; Weizman T; Melamed Y; Adelson M; Bleich A
    Isr J Psychiatry Relat Sci; 2006; 43(2):126-36. PubMed ID: 16910375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Organizational and client determinants of cost in outpatient substance abuse treatment.
    Beaston-Blaakman A; Shepard D; Horgan C; Ritter G
    J Ment Health Policy Econ; 2007 Mar; 10(1):3-13. PubMed ID: 17417043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Staff perspectives on facilitating the implementation of hepatitis C services at drug treatment programs.
    Munoz-Plaza CE; Strauss SM; Astone-Twerwll JM; Des Jarlais DC; Hagan H
    J Psychoactive Drugs; 2006 Sep; 38(3):233-41. PubMed ID: 17165366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Referral for chronic hepatitis C treatment from a drug dependency treatment setting.
    Hallinan R; Byrne A; Agho K; Dore GJ
    Drug Alcohol Depend; 2007 Apr; 88(1):49-53. PubMed ID: 17067763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treating hepatitis C virus infection in active substance users.
    Sylvestre DL
    Clin Infect Dis; 2005 Apr; 40 Suppl 5():S321-4. PubMed ID: 15768341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.